Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Earnings Call Summary
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.22M | 50.19M | 52.61M | 66.64M | 81.84M | 65.26M |
| Gross Profit | 25.00M | 21.48M | 23.86M | 24.04M | 39.37M | 37.42M |
| EBITDA | 11.47M | 11.16M | 7.68M | -2.18M | 27.39M | 20.04M |
| Net Income | 6.12M | 6.24M | 2.35M | -10.10M | 15.85M | 11.11M |
Balance Sheet | ||||||
| Total Assets | 82.43M | 81.75M | 80.85M | 89.29M | 115.12M | 101.27M |
| Cash, Cash Equivalents and Short-Term Investments | 16.62M | 13.01M | 6.02M | 11.58M | 20.34M | 21.91M |
| Total Debt | 1.12M | 1.32M | 4.10M | 1.55M | 3.47M | 1.96M |
| Total Liabilities | 9.55M | 8.53M | 12.63M | 14.77M | 20.38M | 23.07M |
| Stockholders Equity | 71.73M | 72.33M | 67.12M | 73.35M | 94.12M | 77.65M |
Cash Flow | ||||||
| Free Cash Flow | 9.47M | 11.41M | -664.00K | 3.86M | 4.59M | 11.16M |
| Operating Cash Flow | 10.71M | 13.66M | 6.31M | 9.69M | 10.24M | 13.81M |
| Investing Cash Flow | -1.84M | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M |
| Financing Cash Flow | -1.44M | -4.08M | -3.65M | -11.04M | -6.16M | -5.21M |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £79.68M | 10.67 | 64.40% | 8.33% | -3.61% | -6.35% | |
67 Neutral | £111.41M | 19.11 | 8.71% | ― | -1.43% | 28.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.76M | 3.51 | 13.26% | ― | -10.20% | 714.29% | |
47 Neutral | £11.17M | -1.11 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £16.95M | -7.11 | -90.48% | ― | 37.39% | -126.19% | |
40 Underperform | £14.20M | -0.23 | 425.97% | ― | -4.48% | 61.09% |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings has completed its share buyback programme, purchasing a final tranche of 159,000 ordinary shares at a weighted average price of 25.6875 pence, bringing total repurchases under the scheme to 17.13 million shares at an average cost of 26.14 pence, with the latest shares held in treasury. Following these transactions, EKF’s issued share capital stands at 435.38 million shares, of which 431.96 million carry voting rights, while a related trade with funds managed by Harwood ensures non-executive director Christopher Mills’ aggregate indirect stake remains at about the same level and below 30% of voting rights, clarifying the ownership structure for investors and the threshold for regulatory disclosures.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 106,000 of its ordinary shares at a volume-weighted average price of 25.7333 pence, with all shares to be held in treasury, reducing the number of shares carrying voting rights to 432,122,112. As part of this buyback, EKF acquired 31,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect beneficial interest remains at around, and does not exceed, 30% of total voting rights, leaving him with an indirect holding of 127,428,000 shares and clarifying the new capital structure for shareholders’ disclosure calculations.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 72,000 of its ordinary shares at a weighted average price of 25.6 pence, with the shares to be held in treasury, leaving 432,228,112 shares in issue carrying voting rights. As part of the buyback, the company acquired 22,000 shares from funds managed by Harwood to ensure that Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest, now 127,459,000 shares, remains around but does not exceed 30% of EKF’s total voting rights, a move that helps manage control thresholds and maintains regulatory compliance for major shareholders.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 280,000 of its ordinary shares at a weighted average price of 26.175 pence, with the shares to be held in treasury, reducing the number of shares in issue carrying voting rights to 432,300,112. As part of the buyback, EKF acquired 80,000 shares from funds managed by Harwood to maintain Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at around 127.5 million shares and ensure his holding does not exceed 30% of the company’s voting rights, a move that fine-tunes EKF’s capital structure and preserves its shareholder governance balance.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics reported modest top-line growth for FY 2025, with revenues up 3% to £51.6m as it continues to prioritise higher-margin product ranges and wind down non-core, low-margin lines. Point-of-care revenues in hematology and diabetes rose 6.5%, and the Life Sciences division grew 7.2%, driven by a 10% increase in β-HB sales and a new fermentation development agreement with a major diagnostics customer that is expected to contribute further in 2026 and potentially benefit from onshoring in the US. Gross margins improved to 51% from 48%, and adjusted EBITDA is expected to rise nearly 10% to £12.4m, in line with market expectations, underlining a stronger profitability base for the company’s five-year growth strategy focused on POC hematology leadership, consolidating its β-HB position and building a world-class CDMO platform. EKF also underscored its balance-sheet strength with £15.8m of year-end cash, no bank borrowings and continued strong cash generation despite deploying £5.1m on growth investment and an on-market share buy-back that has retired 5% of its shares, a move the company highlights as evidence of perceived undervaluation while carefully managing the stake of major shareholder Harwood to avoid triggering a mandatory takeover offer.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 240,000 of its ordinary shares at a volume-weighted average price of 25.7 pence, with the shares to be held in treasury, leaving 432,580,112 ordinary shares carrying voting rights out of a total issued share capital of 435,383,092. As part of the buyback, the company acquired 70,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect beneficial interest, now at 127,561,000 shares, remains at approximately the same level and does not exceed 30% of EKF’s total voting rights, a move that helps manage shareholder concentration and regulatory thresholds while signalling continued capital management activity by the group.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 200,000 of its ordinary shares at 26 pence each, adding them to treasury and leaving 432,820,112 shares in issue carrying voting rights, a move that modestly adjusts its capital structure and may support earnings per share over time. As part of the buyback, the company acquired 59,000 shares from funds managed by Harwood to ensure that Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest remains around, but does not exceed, 30% of EKF’s total voting rights, clarifying ownership dynamics for shareholders and regulators.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 56,000 of its own ordinary shares at 26 pence each, placing them in treasury and leaving 433,020,112 shares in issue with voting rights. As part of the buyback, the company acquired 16,000 shares from funds managed by Harwood, a move designed to keep Non-Executive Director Christopher Mills’ aggregate indirect stake at about its previous level and below 30% of EKF’s voting rights, thereby managing ownership concentration and regulatory thresholds for significant shareholders.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 142,000 ordinary shares at a price of 26 pence per share, with the shares to be held in treasury, leaving 433,076,112 shares in issue carrying voting rights. As part of the buyback, the company acquired 42,000 shares from funds managed by Harwood, a move designed to keep non-executive director Christopher Mills’ aggregate indirect holding at about 127.7 million shares and ensure his interest remains around but below 30% of EKF’s total voting rights, clarifying the updated capital structure and major shareholder position for investors.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 200,000 of its ordinary shares at a weighted average price of 25.989p per share, placing the stock in treasury and leaving 433,218,112 shares in issue with voting rights out of a total issued share capital of 435,383,092. As part of this buyback, the company acquired 59,000 shares from funds managed by Harwood, ensuring that non-executive director Christopher Mills’ aggregate indirect stake remains at roughly 30% of voting rights, a move that fine-tunes the shareholder structure while supporting capital management objectives and maintaining regulatory thresholds for major shareholdings.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has bought back 267,000 of its ordinary shares at a price of 26 pence each, placing the repurchased stock into treasury and leaving 433,418,112 shares in issue with voting rights. As part of the transaction, the company acquired 79,000 shares from funds managed by Harwood in order to keep Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at roughly the same proportion of total voting rights and below the 30% threshold, a move that fine-tunes EKF’s capital structure and maintains regulatory comfort for major shareholders.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 142,000 of its own ordinary shares at a weighted average price of 26.4 pence, placing the shares into treasury and leaving 433,685,112 shares in issue with voting rights, a move that marginally adjusts the company’s capital structure and provides a new denominator for major shareholding disclosures. As part of this buyback, EKF also acquired 42,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 127,886,000 shares, remains around but below 30% of the company’s voting rights, addressing regulatory thresholds and preserving the existing balance of shareholder control.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 142,000 of its ordinary shares at 26.1 pence each, with the shares to be held in treasury, leaving 433,827,112 shares in issue carrying voting rights. As part of the transaction, the company acquired 42,000 shares from funds managed by Harwood to keep non-executive director Christopher Mills’ aggregate indirect holding at around its previous level and below 30% of voting rights, a move that fine-tunes EKF’s capital structure and major shareholder positioning while providing clarity for investors on future disclosure thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 43,000 ordinary shares at a weighted average price of 25.56 pence, with the shares to be held in treasury, leaving 433,969,112 shares in issue carrying voting rights. As part of the transaction, the company bought 13,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 127,970,000 shares, remains at around but not above 30% of EKF’s total voting rights, a move that fine-tunes the firm’s capital structure and major shareholder positioning for regulatory purposes.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 639,000 ordinary shares at a volume-weighted average price of 24.96p per share, with the shares to be held in treasury, leaving 434,012,112 shares carrying voting rights out of a total issued share capital of 435,383,092. As part of the buyback, the company acquired 189,000 shares from funds managed by Harwood Capital, a move designed to keep Non-Executive Director Christopher Mills’ aggregate indirect beneficial interest at roughly its previous level and below 30% of voting rights, thereby managing ownership concentration and maintaining compliance with UK disclosure and takeover thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has bought back 71,000 of its own ordinary shares at 25.5 pence each, all of which will be held in treasury, reducing the number of shares in circulation to 434,651,112 with voting rights. As part of the transaction, the company acquired 21,000 shares from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect interest remains around, but does not exceed, 30% of EKF’s total voting rights, leaving him with an indirect holding of 128,172,000 shares, a move that consolidates the capital structure while managing a significant shareholder’s regulatory threshold.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 71,000 of its own ordinary shares at a weighted average price of 25.3 pence, with the shares to be held in treasury, leaving 434,722,112 shares in issue carrying voting rights. As part of the buyback, 21,000 shares were acquired from funds managed by Harwood to ensure that non-executive director Christopher Mills’ aggregate indirect holding, now 128,193,000 shares, remains at around 30% of the company’s voting rights, a move that stabilises the shareholder structure and supports compliance with UK disclosure and takeover thresholds.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 355,000 of its ordinary shares at a volume-weighted average price of 25.62 pence, with all shares to be held in treasury, reducing the number of shares in issue carrying voting rights to 434,793,112. As part of the buyback, the company acquired 105,000 shares from funds managed by Harwood, structured to keep non-executive director Christopher Mills’ aggregate indirect interest at around 30% of EKF’s voting rights, a move that fine-tunes the company’s capital structure while managing significant shareholder influence and regulatory thresholds for disclosure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings has repurchased 93,980 of its ordinary shares at 25.5 pence each, holding the stock in treasury and reducing the number of shares in issue that carry voting rights to 435,148,112. The buyback included the purchase of 28,000 shares from funds managed by Harwood, structured to keep non-executive director Christopher Mills’ aggregate indirect stake at roughly the same level and below 30% of voting rights, a move that helps manage shareholder concentration while signalling continued capital management activity by the diagnostics group.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the repurchase of 141,000 of its ordinary shares at an average price of 23.5 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain stakeholder interests, ensuring that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the total voting rights. The transaction reflects EKF’s commitment to optimizing its capital structure and could potentially enhance shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced the cancellation of 13,710,698 ordinary shares as part of its share buyback program, effective from December 2, 2025. This cancellation reduces the company’s total issued share capital to 435,383,092 ordinary shares, each with one voting right, which will impact shareholders’ calculations under the FCA’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 4,395,062 of its ordinary shares at a price of 25 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the indirect beneficial interest of Mr. Mills, a significant stakeholder, at a stable level. The buyback is expected to impact the company’s voting rights, with the total number of shares carrying voting rights now at 435,383,092. This transaction reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the purchase of 141,000 of its ordinary shares at a weighted average price of 25.8 pence per share, which will be held in treasury. This share buyback is part of a strategic move to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize its capital structure and maintain shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced an extension to its share buyback program, intending to purchase additional ordinary shares worth approximately £1.0 million. This move follows previous buyback extensions and aims to hold the shares in treasury. The company recently acquired 1,844,000 ordinary shares at a weighted average price of 25.8 pence per share. This buyback is part of a strategy to manage the company’s share capital and maintain shareholder value, with implications for the company’s market positioning and stakeholder interests, particularly in maintaining the indirect beneficial interest of Mr. Mills, a significant shareholder.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced that its total issued share capital consists of 449,093,790 ordinary shares, with 7,330,636 shares held in treasury, resulting in 441,763,154 shares carrying voting rights. This information is crucial for shareholders to determine their interest in the company’s share capital under the Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has executed a share buyback, acquiring 309,384 ordinary shares at a weighted average price of 26.6 pence per share, which will be held in treasury. This move is part of a strategic decision to manage its share capital and maintain the aggregate indirect beneficial interest of a key stakeholder, Mr. Mills, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The transaction reflects EKF’s ongoing efforts to optimize shareholder value and manage its equity structure effectively, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.